NEW YORK, NY / ACCESSWIRE / July 19, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Bloom Energy Corporation (BE)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/bloom-energy-corporation-loss-submission-form?prid=2515&wire=1
Lead Plaintiff Deadline: July 29, 2019
Class Period: on behalf of all persons who purchased or otherwise acquired Bloom Energy common stock pursuant or traceable to Bloom Energy’s July 2018 IPO.
The complaint alleges that Bloom Energy's Registration Statement was materially misleading as it failed to disclose known events and trends that were severely affecting the Company’s business and that made investment in Bloom Energy significantly riskier than presented in the Registration Statement. In particular, the Registration Statement failed to disclose that the Company was experiencing material construction delays. These construction delays would cause system deployments (or “acceptances” as Defendants referred to them) to fall significantly below even the low end of the Company’s previously announced guidance.
While the Registration Statement purported to warn of risks that “may arise,” which could materially affect the Company, in actuality these material negative events were already occurring. As a result, the representations and purported risk disclosures were false and misleading because, by the time of the IPO, construction delays had already impacted or would soon impact Bloom Energy’s ability to deliver acceptances in line with its guidance.
Heron Therapeutics, Inc. (HRTX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/heron-therapeutics-inc-loss-submission-form?prid=2515&wire=1
Lead Plaintiff Deadline: August 5, 2019
Class Period: October 31, 2018 to April 30, 2019
Allegations against HRTX include that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.
Diebold Nixdorf, Incorporated (DBD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/diebold-nixdorf-incorporated-loss-submission-form?prid=2515&wire=1
Lead Plaintiff Deadline: September 3, 2019
Class Period: February 14, 2017 to July 4, 2017
Allegations against DBD include that: (1) that, as a result of the Wincor acquisition and related integration, the Company was less focused on its core business; (2) that the Company expected certain customers would not renew their service contracts (i.e. contract runoff); (3) that the Company was not adequately prepared to staff service technicians; (4) that, as a result of the expected contract runoff, the Company would suffer a shortage of adequately trained service technicians; (5) that, as a result, the Company would suffer margin pressure in its services segment; (6) that, as a result of the foregoing, the Company would lose market share; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE:The Law Offices of Vincent Wong
View source version on accesswire.com: